What is Non-Calcified Plaque?
Non-calcified plaque (also called noncalcified or soft plaque) is atherosclerotic plaque in coronary arteries that lacks calcium deposits and consists primarily of lipid-rich cores, fibrous tissue, and inflammatory cells—this is the most dangerous type of plaque because it is prone to rupture and can cause myocardial infarction even without causing significant arterial narrowing. 1
Composition and Clinical Significance
Non-calcified plaque represents the "vulnerable" or "unstable" form of coronary atherosclerosis. According to the American Heart Association, unstable plaques are generally higher in lipid content than stable plaques, with most ruptures occurring in plaques containing a soft, lipid-rich core covered by a thin, inflamed fibrous cap 1. These rupture-prone plaques are 7 times more likely to ulcerate than more severe, extensive plaques 1.
Key Characteristics:
- Lipid-rich core: Contains cholesterol and inflammatory cells
- Thin fibrous cap: Typically around 70 µm thick (too thin to detect with current imaging)
- Inflammatory cells: Active inflammation makes the plaque unstable
- Positive remodeling: The artery wall expands outward, preserving lumen size despite plaque growth 1
Why Non-Calcified Plaque Matters for Mortality and Morbidity
The critical danger is that myocardial infarction can result from rupture of vulnerable non-calcified plaque in the absence of significant luminal stenosis 1. This means patients can have a heart attack even when their arteries don't appear severely blocked on traditional angiography.
Prevalence and Risk:
- Non-calcified plaque is present in up to 10% of patients with a coronary calcium score of 0 2
- In patients presenting with suspected acute coronary syndrome, 39% of plaques are purely non-calcified, 47% are mixed, and only 14% are purely calcified 3
- The absence of coronary calcium does not reliably exclude the presence of significant atherosclerosis 3
- Non-calcified plaque accounts for most of the total plaque volume at all ages, especially in men and women <55 years (>70% and >80%, respectively) 4
Detection and Imaging
Non-calcified plaque can be detected on coronary CT angiography (CCTA) but not on calcium scoring alone 1. On CT imaging:
- Lowest CT density values (<30 Hounsfield units) correlate with lipid-laden plaque 1, 5
- Intermediate densities correlate with fibrous lesions 1
- Current spatial resolution limitations (750 µm for CT, 500-780 µm for MRI) cannot detect the thin fibrous cap (70 µm) that defines vulnerability 1
High-Risk Plaque Features on CCTA:
According to CAD-RADS 2.0 guidelines, a combination of two or more of the following features designates a plaque as high-risk 6, 5:
- Low attenuation plaque (<30 HU)
- Positive remodeling (vessel diameter ratio >1.1)
- Spotty calcium (punctate calcium within plaque)
- "Napkin ring sign" (peripheral rim of higher attenuation surrounding low-attenuation core)
Clinical Implications for Quality of Life and Outcomes
High-risk non-calcified plaques independently predict major adverse cardiovascular events (MACE) with an odds ratio of 12.1 compared to low-risk plaques 7. Recent data shows:
- Total plaque burden ≥35% and non-calcified plaque burden ≥20% are each associated with nearly a 2-fold increase in MACE risk 8
- In high cardiovascular risk populations with CAC scores 0-100, patients with discrete non-calcified plaque had a 5.70% adverse cardiovascular event rate at two years 9
- Non-calcified plaque volume increases at approximately 4.9 mm³/year even in patients without lipid-lowering therapy 10
Important Caveat:
Assessment of non-calcified plaque remains limited to studies of very high image quality and may not pertain to average clinical applications 1. Visualization is particularly limited by plaque and vessel size—smaller plaques in smaller coronary sections are not accurately characterized 1.
Treatment Response
Intensive statin therapy can decelerate non-calcified plaque progression, with evidence showing plaque-volume growth slowing from approximately 18.6% to 12.6% per year with high-intensity rosuvastatin 11. This demonstrates that non-calcified plaque is modifiable with aggressive lipid-lowering therapy, even in patients with zero calcium scores 11.